ArticleCost effectiveness and resource allocation : C/E2025

Cost-effectiveness of nirmatrelvir/ritonavir in COVID-19 patient groups at high risk for progression to severe COVID-19 in the Netherlands.

Carlos H Arteaga Duarte et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.